OBJECTIVE: To evaluate the immediate and long-term effectiveness of mindfulness-based stress reduction (MBSR) on biological and symptomatological markers of health among human immunodeficiency virus-positive (HIV+) patients in Tehran, Iran. METHODS: Using a randomized controlled trial design, data from 173 HIV+ patients (CD4 count > 250) not yet receiving antiretroviral therapy, who participated in either an 8-week MBSR (n = 87) or a brief education and support condition (n = 86) at the Imam Khomeini Hospital, were analyzed. Assessments included CD4 count, Symptom Checklist-90-Revised (SCL-90R), and Medical Symptom Checklist (MSCL) at baseline, immediate post-treatment, and at the 3-, 6-, 9-, and 12-month follow-up periods. RESULTS:The treatment-adherent sample had a mean (standard deviation) age of 35.1 (6.5) years and 69% were male. Linear mixed-model estimates indicated that, in the MBSR condition, the mean CD4 count increased from baseline up to 9 months after treatment and then returned to baseline level at 12 months. Improvements in mean SCL-90R (up to 6 months) and MSCL (up to 12 months) scores were observed for the MBSR condition, whereas education and support condition scores remained the same over time; however, only MSCL improvements significantly differed between groups and these changes lasted up to the final assessment. CONCLUSIONS: Findings suggest that among treatment-adherent Iranian HIV+ patients not yet receiving antiretroviral drug treatment, MBSR seems to have the strongest potential to improve self-reported medical symptoms. TRIAL REGISTRATION: Iranian Registry of Clinical Trials: IRCT201106084076N2.
RCT Entities:
OBJECTIVE: To evaluate the immediate and long-term effectiveness of mindfulness-based stress reduction (MBSR) on biological and symptomatological markers of health among human immunodeficiency virus-positive (HIV+) patients in Tehran, Iran. METHODS: Using a randomized controlled trial design, data from 173 HIV+ patients (CD4 count > 250) not yet receiving antiretroviral therapy, who participated in either an 8-week MBSR (n = 87) or a brief education and support condition (n = 86) at the Imam Khomeini Hospital, were analyzed. Assessments included CD4 count, Symptom Checklist-90-Revised (SCL-90R), and Medical Symptom Checklist (MSCL) at baseline, immediate post-treatment, and at the 3-, 6-, 9-, and 12-month follow-up periods. RESULTS: The treatment-adherent sample had a mean (standard deviation) age of 35.1 (6.5) years and 69% were male. Linear mixed-model estimates indicated that, in the MBSR condition, the mean CD4 count increased from baseline up to 9 months after treatment and then returned to baseline level at 12 months. Improvements in mean SCL-90R (up to 6 months) and MSCL (up to 12 months) scores were observed for the MBSR condition, whereas education and support condition scores remained the same over time; however, only MSCL improvements significantly differed between groups and these changes lasted up to the final assessment. CONCLUSIONS: Findings suggest that among treatment-adherent Iranian HIV+ patients not yet receiving antiretroviral drug treatment, MBSR seems to have the strongest potential to improve self-reported medical symptoms. TRIAL REGISTRATION: Iranian Registry of Clinical Trials: IRCT201106084076N2.
Authors: Erica M S Sibinga; Miriam Stewart; Trish Magyari; Cora K Welsh; Nancy Hutton; Jonathan M Ellen Journal: Explore (NY) Date: 2008 Jan-Feb Impact factor: 1.775
Authors: Erica K Sloan; John P Capitanio; Ross P Tarara; Sally P Mendoza; William A Mason; Steve W Cole Journal: J Neurosci Date: 2007-08-15 Impact factor: 6.167
Authors: Nancy L McCain; D Patricia Gray; R K Elswick; Jolynne W Robins; Inez Tuck; Jeanne M Walter; Sarah M Rausch; Jessica McKinney Ketchum Journal: J Consult Clin Psychol Date: 2008-06
Authors: Michael H Antoni; Adam W Carrico; Ron E Durán; Susan Spitzer; Frank Penedo; Gail Ironson; Mary Ann Fletcher; Nancy Klimas; Neil Schneiderman Journal: Psychosom Med Date: 2006 Jan-Feb Impact factor: 4.312
Authors: Frederick M Hecht; Judith T Moskowitz; Patricia Moran; Elissa S Epel; Peter Bacchetti; Michael Acree; Margaret E Kemeny; Wendy Berry Mendes; Larissa G Duncan; Helen Weng; Jay A Levy; Steven G Deeks; Susan Folkman Journal: Brain Behav Immun Date: 2018-05-26 Impact factor: 7.217
Authors: Daisy R Singla; Brandon A Kohrt; Laura K Murray; Arpita Anand; Bruce F Chorpita; Vikram Patel Journal: Annu Rev Clin Psychol Date: 2017-05-08 Impact factor: 18.561
Authors: Madhav Goyal; Sonal Singh; Erica M S Sibinga; Neda F Gould; Anastasia Rowland-Seymour; Ritu Sharma; Zackary Berger; Dana Sleicher; David D Maron; Hasan M Shihab; Padmini D Ranasinghe; Shauna Linn; Shonali Saha; Eric B Bass; Jennifer A Haythornthwaite Journal: JAMA Intern Med Date: 2014-03 Impact factor: 21.873
Authors: Mary Catherine George; Arada Wongmek; Michelle Kaku; Alexandra Nmashie; Jessica Robinson-Papp Journal: Behav Med Date: 2015-12-11 Impact factor: 3.104